Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: S. aureus monoclonal antibody - Inhibitex; Staphylococcus aureus monoclonal antibody - Inhibitex; Aurexis; Humanised mAb 12-9 - Inhibitex; INH-H2002

Latest Information Update: 17 Feb 2012

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inhibitex
  • Class Antibacterials; Antitoxins; Monoclonal antibodies
  • Mechanism of Action Cell adhesion molecule inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Suspended Staphylococcal infections

Most Recent Events

  • 14 Feb 2012 Inhibitex has been acquired by Bristol-Myers Squibb
  • 22 Nov 2010 Tefibazumab is available for licensing as of 22 Nov 2010. http://www.inhibitex.com
  • 21 Aug 2007 Tefibazumab is available for licensing (http://www.inhibitex.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top